Tune in to our upcoming broadcast to learn more about advances in the treatment of tenosynovial giant cell tumor. Register today!

Why Immune Cell Expression in Breast Cancer is Important

LEISHA A. EMENS, MD, PHD
Monday, October 07, 2019


According to Leisha A. Emens, MD, PhD, professor of medicine at the UPMC Hillman Cancer Center, findings of the KATE2 trial showed that the addition of atezolizumab (Tecentriq) to TDM1 (Kadcyla) did not improve progression free survival (PFS) overall but did improve PFS in patients PDL1 expression in their immune cells.

At the European Society of Medical Oncology (ESMO) Congress 2019, OncLive®, a sister publication of Oncology Nursing News®, had the chance to interview Emens and discuss these findings as well as why researchers chose to asses for PDL1 in immune cells over other methods.    

TRANSCRIPTION
SP142 is an assay that has been co-developed along with atezolizumab, and I think the priority at the beginning of this clinical development program was to really focus on immune cells, because the target of the drug is unleashing immune cells, particularly T-cells, and their ability to attack the tumor. It turns out that in breast cancer there is not a significant level of tumor cell expression above and beyond what you find in immune cells, so at least for breast cancer, it appears that immune cell expression is the most important. 

 

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.